Notably, in NF1-related MPNSTs, the loss of CDKN2A may act synergistically with epigenetic silencing and mechanical restructuring at the cellular level, enhancing tumor heterogeneity and drug resistance. This evidence concerns the gene NF1 and neoplasm.